Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Divestment of antimigraine treatment from Glaxo Wellcome to Zeneca

Sep. 13, 1996

Controlled-release oral analgesic formulation claimed by Euroceltique

Sep. 13, 1996

Chiron describes a new opiate receptor ligand

Sep. 13, 1996

Delta-opioid agonists for pain

Sep. 13, 1996

NK1 antagonists from Glaxo Wellcome

Sep. 13, 1996

Another NeuroSearch compound for nerve degeneration

Sep. 6, 1996

NeuroSearch compound for the treatment of brain damage

Sep. 6, 1996

New adenosine A3 receptor antagonist reported at ACS

Sep. 6, 1996

Potential new treatment for Alzheimer's disease disclosed by SIBIA Neurosciences

Sep. 6, 1996

INSERM and Bioprojet describe a new histamine H3 receptor antagonist

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...